Pfizer EBIT 2010-2024 | PFE
Pfizer annual and quarterly EBIT history from 2010 to 2024. EBIT can be defined as earnings before interest and taxes.
- Pfizer EBIT for the quarter ending June 30, 2024 was $1.003B, a 54.28% decline year-over-year.
- Pfizer EBIT for the twelve months ending June 30, 2024 was $-3.411B, a 115.46% decline year-over-year.
- Pfizer 2023 annual EBIT was $0.222B, a 99.36% decline from 2022.
- Pfizer 2022 annual EBIT was $34.944B, a 79.82% increase from 2021.
- Pfizer 2021 annual EBIT was $19.433B, a 135.55% increase from 2020.
Pfizer Annual EBIT
(Millions of US $) |
| 2023 |
$222 |
| 2022 |
$34,944 |
| 2021 |
$19,433 |
| 2020 |
$8,250 |
| 2019 |
$6,710 |
| 2018 |
$5,672 |
| 2017 |
$13,722 |
| 2016 |
$12,145 |
| 2015 |
$11,824 |
| 2014 |
$13,249 |
| 2013 |
$15,184 |
| 2012 |
$15,264 |
| 2011 |
$13,967 |
| 2010 |
$13,412 |
| 2009 |
$10,959 |
Pfizer Quarterly EBIT
(Millions of US $) |
| 2024-06-30 |
$1,003 |
| 2024-03-31 |
$4,102 |
| 2023-12-31 |
$-5,086 |
| 2023-09-30 |
$-3,430 |
| 2023-06-30 |
$2,194 |
| 2023-03-31 |
$6,544 |
| 2022-12-31 |
$4,381 |
| 2022-09-30 |
$8,943 |
| 2022-06-30 |
$12,219 |
| 2022-03-31 |
$9,401 |
| 2021-12-31 |
$2,991 |
| 2021-09-30 |
$6,147 |
| 2021-06-30 |
$5,606 |
| 2021-03-31 |
$4,689 |
| 2020-12-31 |
$703 |
| 2020-09-30 |
$2,448 |
| 2020-06-30 |
$2,072 |
| 2020-03-31 |
$3,027 |
| 2019-12-31 |
$-4,928 |
| 2019-09-30 |
$2,958 |
| 2019-06-30 |
$4,266 |
| 2019-03-31 |
$4,414 |
| 2018-12-31 |
$-6,017 |
| 2018-09-30 |
$3,764 |
| 2018-06-30 |
$3,976 |
| 2018-03-31 |
$3,949 |
| 2017-12-31 |
$2,307 |
| 2017-09-30 |
$3,664 |
| 2017-06-30 |
$3,741 |
| 2017-03-31 |
$4,010 |
| 2016-12-31 |
$1,756 |
| 2016-09-30 |
$3,021 |
| 2016-06-30 |
$3,477 |
| 2016-03-31 |
$3,891 |
| 2015-12-31 |
$1,834 |
| 2015-09-30 |
$3,358 |
| 2015-06-30 |
$3,595 |
| 2015-03-31 |
$3,037 |
| 2014-12-31 |
$2,147 |
| 2014-09-30 |
$3,682 |
| 2014-06-30 |
$3,950 |
| 2014-03-31 |
$3,470 |
| 2013-12-31 |
$3,043 |
| 2013-09-30 |
$3,984 |
| 2013-06-30 |
$4,287 |
| 2013-03-31 |
$3,870 |
| 2012-12-31 |
$2,560 |
| 2012-09-30 |
$3,743 |
| 2012-06-30 |
$4,868 |
| 2012-03-31 |
$4,093 |
| 2011-12-31 |
$1,913 |
| 2011-09-30 |
$4,088 |
| 2011-06-30 |
$4,021 |
| 2011-03-31 |
$3,945 |
| 2010-12-31 |
$1,887 |
| 2010-09-30 |
$3,763 |
| 2010-06-30 |
$4,201 |
| 2010-03-31 |
$3,561 |
| 2009-12-31 |
$-39 |
| 2009-09-30 |
$4,131 |
| 2009-06-30 |
$3,121 |
| 2009-03-31 |
$3,746 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$168.584B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
